Business Wire

PPG, PPG Foundation invested $16.2 million in communities worldwide in 2022

Share

PPG (NYSE:PPG) and the PPG Foundation today announced that they invested $16.2 million in 2022, an increase of more than $2.5 million over 2021, to support more than 650 community partners and programs worldwide that are focused on advancing education and delivering community sustainability while encouraging PPG employee volunteerism.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005215/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PPG completed 87 COLORFUL COMMUNITIES® projects in 2022 in 25 countries. The program has now completed 473 projects since 2015, involving more than 23,000 employee and community volunteers. (Photo: Business Wire)

“In 2022, we activated the power of our employee volunteers, color and paint expertise, and focus on STEM advancement to build better, brighter communities,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “From helping students thrive to aiding our neighbors in times of need, our community engagement activities supported our company’s purpose to 'protect and beautify the world.'”

Highlights of the 2022 community engagement commitments include:

  • $9.1+ million to build the next generation of science, technology, engineering and mathematics ( STEM) leaders.
    • The PPG Foundation and Discovery World Museum in Milwaukee opened the PPG STEM Lab to engage young minds who aspire to be scientists, engineers, and innovators.
    • In Uithoorn, the Netherlands, PPG joined Centrum JongerenCommunicatie Chemie (C3) to launch an online STEM education platform and encourage future STEM careers.
    • PPG supported the Girls in Tech initiative in Sumaré, Brazil with non-profit organization Casa Hacker to inspire women to work in technical fields and to offer training in electronics, computer programming, robotics and 3D printing.
  • 70% progress toward the commitment to invest $20 million by 2025 supporting programs for black communities and people of color in the U.S.
    • Programs including the Latino Community Center in Pittsburgh, Pennsylvania’s youth internship and career support initiative and the American Printing House for the Blind’s STEM symposium, PPG partnerships helped students find the connections between STEM ideas and real-life innovations and careers.
    • The PPG Foundation supported diverse students entering advanced STEM studies through partnerships with higher learning and professional organizations, including the University of Wisconsin-Madison’s Bridge to the Chemistry Doctorate Program and American Institute of Chemical Engineers’ Future of STEM Scholars Initiative.
    • Grantmaking also included initiatives with organizations such as the NAACP Legal Defense Fund and Equal Justice Initiative.
  • $6.1+ million to community sustainability through colorful spaces, disaster and humanitarian relief:
    • PPG provided humanitarian relief and educational support for the urgent and long-term recovery needs of Ukrainian refugees.
    • The PPG Foundation contributed to the local emergency relief and recovery efforts of the American Red Cross following Hurricane Ian in Florida, USA and Hurricane Fiona in Puerto Rico.
  • 87 COLORFUL COMMUNITIES® projects completed in 2022 in 25 countries:
    • PPG’s global Colorful Communities program has now completed 473 projects since 2015 and exceeded the initial $10 million commitment, dedicating more than $11 million to support this important initiative. More than 23,000 employee and community volunteers have used PPG paint products to bring color and brightness to community assets in nearly 50 countries, positively impacting more than 8.2 million people.

Throughout July 2022, the Colorful Communities program transformed 36 schools and learning spaces through the New Paint for a New Start campaign. More than 1,000 PPG volunteers took part in the initiative, which benefited more than 23,000 students and educators.

PPG provided more than $1 million to fund this initiative leading to transformations including:

  • Lorenzo Cobianchi Secondary School in Verbania, Italy : After our volunteers painted the chemistry building’s corridors, classrooms and common areas, 2,000 students now have access to a colorful space for science exploration.
  • TEDA No.1 Kindergarten in Tianjin, China : PPG volunteers created engaging spaces for students to learn and grow and revitalized the building’s exterior after it faced damage due to weathering.
  • Ciudad de Brasilia school in Santiago, Chile: More than 115 volunteers helped 550 students by painting the walls of the school’s courtyard and corridors, including a nature-themed mural made from a student's drawing.
  • Rayburn Elementary STEAM Academy in Grand Prairie, Texas: PPG and Heart of America teamed up to revitalize a library, shared learning area, and painted four vibrant science, technology, engineering, arts and mathematics (STEAM) murals.

“Resiliency, discovery and connection were among the key themes of our community investments in 2022. With the support of our partners worldwide we transformed classrooms, helped communities facing hardships, and encouraged students of all ages to pursue careers in STEM,” said Dunn.

Learn more about PPG and the PPG Foundation’s investments in 2022.

PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested $16.2 million in 2022, supporting hundreds of organizations across more than 35 countries. By investing in educational opportunities, we help grow today’s skilled workforce and develop tomorrow’s innovators in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more at communities.ppg.com.

PPG: WE PROTECT AND BEAUTIFY THE WORLD®

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

Colorful Communities, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.

CATEGORY Community Affairs

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mark Silvey
Corporate Communications
+1 412-434-3046
silvey@ppg.com
www.ppgcommunities.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye